USANA Lowers FY26 Profit Outlook as Hiya and Rise Offset Core Gains

What happened

USANA cut its 2026 adjusted EBITDA guidance to approximately $77 million from a prior outlook of $80.5 million, while maintaining net sales near $900 million. The revision reflects weaker sales at the small Rise Wellness brand and increased marketing investment at Hiya, which offset stronger profitability in the core legacy nutrition business. This implies a consolidated EBITDA margin of roughly 8.6%, still below management’s historical target of 10% and below the master report’s base case of 9–10%. The improved core nutrition performance is encouraging but insufficient to offset the dilutive impact of newer acquisitions. Investors should view the guidance cut as a sign that the turnaround remains unproven and margin recovery is further delayed.

Implication

The revised FY26 outlook indicates the company is likely to remain in a sub-10% EBITDA margin environment for at least another year, with Hiya’s marketing intensity and Rise’s weakness offsetting core improvements. The market may react negatively to the reduced EBITDA, but the stock is already cheap at ~0.75x book and ~2.5x EV/EBITDA. However, until there is clear evidence that Hiya can scale profitably and direct-selling customer declines have bottomed, the risk of further guidance cuts or goodwill impairment remains. Investors should monitor Hiya’s subscriber growth, marketing efficiency, and direct-selling active customer trends over the next two quarters before considering a more constructive stance. A break below $18 (the master report’s attractive entry) could offer a better risk/reward if fundamentals stabilize, but currently the wait-and-see approach remains prudent.

Thesis delta

The latest guidance cut reinforces the master report’s view that USANA’s margin recovery is fragile and further delayed. While core nutrition shows relative strength, the consolidated business remains burdened by Hiya’s marketing spend and Rise’s underperformance, pushing the margin target further out. This does not change the rating but extends the evidence needed for re-rating, with the base case implied value likely to be nudged lower if the margin trend persists.